DB:0JVN

Stock Analysis Report

Executive Summary

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has iBio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0JVN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-14.2%

0JVN

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-67.8%

0JVN

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: 0JVN underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: 0JVN underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

0JVNIndustryMarket
7 Day-14.2%-4.1%-5.7%
30 Day7.8%-8.2%-5.7%
90 Day200.5%-2.0%-3.6%
1 Year-67.8%-67.8%4.0%3.7%9.3%6.1%
3 Year-91.4%-91.4%38.2%36.7%8.9%-0.7%
5 Year-96.6%-96.6%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is iBio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is iBio undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether iBio is trading at an attractive price based on the cash flow it is expected to produce in the future. But as iBio has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is iBio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iBio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has iBio performed over the past 5 years?

-28.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0JVN is currently unprofitable.

Growing Profit Margin: 0JVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0JVN is unprofitable, and losses have increased over the past 5 years at a rate of -28.3% per year.

Accelerating Growth: Unable to compare 0JVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0JVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 0JVN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is iBio's financial position?


Financial Position Analysis

Short Term Liabilities: 0JVN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 0JVN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 0JVN is debt free.

Reducing Debt: 0JVN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 0JVN has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 0JVN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0JVN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 0JVN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.3% each year


Next Steps

Dividend

What is iBio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 0JVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0JVN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0JVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0JVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0JVN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Robert Kay (79yo)

11.5yrs

Tenure

US$347,604

Compensation

Mr. Robert B. Kay serves as Managing Director of Integrated BioPharma, Inc. He serves as a Principal, Co-Owner and Chairman of Seaway Biltmore, Inc., a hotel ownership and management company. Mr. Kay serve ...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD347.60K) is about average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Kay
Executive Chairman & CEO11.5yrsUS$347.60k0.028% $6.0k
Robert Erwin
President11.5yrsUS$275.00kno data
James Mullaney
Chief Financial Officer2.9yrsUS$319.17kno data
Renato Lobo
Chief Medical Officer0yrsno datano data
R. Holtz
President of iBio CDMO1.1yrsno datano data
Carlos Picosse
Chief Executive Officer of IBio Brazil6.3yrsno datano data
Elizabeth Moyle
Secretary0yrsno datano data

6.3yrs

Average Tenure

66yo

Average Age

Experienced Management: 0JVN's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Kay
Executive Chairman & CEO11.5yrsUS$347.60k0.028% $6.0k
Seymour Flug
Independent Director7.2yrsUS$51.87kno data
John McKey
Independent Director11.5yrsUS$51.87k0.064% $13.9k
Glenn Chang
Independent Director11.5yrsUS$51.87k0.0016% $345.2
Vidadi Yusibov
Member of Scientific Advisory Board15.4yrsno datano data
James Hill
Independent Director11.5yrsUS$76.87k0.0020% $427.7
Philip Russell
Independent Director9.9yrsUS$51.87kno data
Timothy Blackwell
Member of Clinical Advisory Board5.6yrsno datano data
Richard Silver
Member of Clinical Advisory Board5.6yrsno datano data
J. Huggins
Member of Clinical Advisory Board5.6yrsno datano data

10.7yrs

Average Tenure

76yo

Average Age

Experienced Board: 0JVN's board of directors are seasoned and experienced ( 10.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 63.6%.


Top Shareholders

Company Information

iBio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iBio, Inc.
  • Ticker: 0JVN
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$23.621m
  • Listing Market Cap: US$21.712m
  • Shares outstanding: 76.20m
  • Website: https://www.ibioinc.com

Number of Employees


Location

  • iBio, Inc.
  • 600 Madison Avenue
  • Suite 1601
  • New York
  • New York
  • 10022
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IBIOAMEX (NYSE MKT LLC)YesCommon StockUSUSDAug 2008
0JVNDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2008

Biography

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company’s services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 22:41
End of Day Share Price2020/02/25 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.